Chiltern Finalizes Acquisition of Theorem Clinical Research

Published on: 

Company News Release

(London, U.K., and Wilmington, N.C.; Sept. 14, 2015) Chiltern, a leading global contract research organization (CRO), has completed its acquisition of Theorem Clinical Research, strengthening its position as the largest mid-sized provider of comprehensive, yet flexible and responsive, clinical development services.


Chiltern now comprises 3,700 people across 47 countries, expanding Chiltern’s footprint in Europe, North America and Asia-Pacific. The acquisition enhances Chiltern’s OncologyBiopharma and Source offerings, broadens its therapeutic expertise and establishes new capabilities in medical device and diagnostics, clinical analytics and clinical supplies.



“By bringing Chiltern and Theorem together, we have created a unique, mid-sized research partner focused on providing exceptional scientific expertise and personal service,” said Dr. Jim Esinhart, Chiltern CEO. “Clients can expect the same high level of service, now with expanded capabilities. Senior leadership will still be involved in running trials.”


“The acquisition of Theorem marks an important milestone for Chiltern,” said Nick Thornton, Chiltern chairman. “We stayed true to our mission to be a responsive, client-centric mid-sized provider, yet we enhanced our geographic coverage and service offerings in key areas. We are delighted to welcome the dynamic Theorem team to Chiltern and are pleased to announce that Dr. John Potthoff, Theorem’s president and CEO, has joined our board as a non-executive director.”